Daniel Castellano路 @cdanicas 路 X路路 15 hours agoScore70
Body
馃幆 #ESMO26 3潞 day Proffered paper GU non-prostate ca. Ph 1 results of XmAb819, a novel ENPP3 x CD3 bispecific, in mRCC.@montypal
馃憠 ORR 30%, CRS G3-4 6.0% with > ORR in> step-dose
@OncoAlert @myESMO @urotoday @DrYukselUrun @g_develasco @GuardConsortium @tompowles1
76 views 路 2 likes 路 2 reposts 路 1 reply
Replies in this thread
- Daniel Castellano@cdanicas
馃幆#ESMO26 Efficacy of AK112 (Ivonescimab), a PD-1/VEGF bispecific antibody, as 1L for first-line favorable-risk aRCC). @Jun Guo 馃憠 26 pts with ORR 65.2% only PR @OncoAlert @myESMO @urotoday @DrYukselUrun @GuardConsortium
Source: Daniel Castellano 路 x.com